Oncosec.com

Onco Sec. OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using our plasmid DNA delivery platform.

Never miss Oncosec.com updates: Start reading the news feed of Onco Sec right away! This site’s feed is stale or rarely updated (or it might be broken for a reason), but you may check related news or Oncosec.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Onco Sec

Subscribe to related news

LSPPPO|HEALTHCARE NEWS|August 08, 2013
via elbiruniblogspotcom.blogspot

LSPPPO|HEALTHCARE NEWS|July 25, 2013 Healthcare News A Weekly Compilation of Clinical Laboratory and Related Information from The Division of Laboratory Science and Standards August 08, 2013 News Highlights Lawmaker Introduces Bill to Close...
Recorded Speakers and Sessions
via ldnresearchtrust

As part of the LDN 2017 Conference we are proud to offer the recorded presentation as outlined below. Cancer: Using the Latest Ideas in Immunotherapy to Improve Outcomes, Survival, and Quality of Life 30m Paul Anderson, NMD Cancer is a pervasive...
Special Report: The Path to Vaccine Profitability
via bioprocessintl

Robust Supply Chains Could Help Pave the Way by Antoinette Lagerwij, Sudeep Suman, Jamie Hintlian, and Kevin Chen Since the business of making vaccines became a commercial proposition, profitability has often been elusive. The economics are difficult...
Course Descriptions
via eastwest

Accounting AC101 | Fall/Winter FINANCIAL ACCOUNTING I 4 CREDITS | COREQUISITE: MT155 will also be examination of the standard setting process, the accrual process, and preparation of financial statements. This course uses a rues-based approach to...
Eight Ways to Leverage the Small-Cap Biotech Bull Market: Ajay Tandon and Jay Albany of SeeThruEquit
via vantagewire

SeeThruEquity’s Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector. In this interview...

Oncosec.com popular pages

Home - OncoSec Medical

Explore Our Technology Learn more about the exciting field of intratumoral immunotherapy and OncoSec’s role as a key leader in this emerging space.
Current Clinical Trials - OncoSec Medical

Current Clinical Trials Multicenter Phase II Trial of Intratumoral pIL-12 plus Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma OBJECTIVES: Assess the safety and overall o...

Combination Approach – OncoSec Medical Incorporated

COMBINATION APPROACH The majority of patients with solid tumors who have been treated with anti-PD-1/PD-L1 therapies do not respond to treatment: this is one of the great challenges in oncology today....